The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I, first-in-human dose study of the dual PI3K/mTOR inhibitor LY3023414 (LY) in patients (pts) with advanced cancer.
 
Kathleen N. Moore
Consulting or Advisory Role - Advaxis; Amgen (Inst); AstraZeneca; Genentech/Roche; Immunogen
Travel, Accommodations, Expenses - AstraZeneca
 
Anna M. Varghese
Research Funding - BioMed Valley Discoveries; Lilly; Taiho Pharmaceutical; Verastem
 
David Michael Hyman
Employment - Memorial Sloan-Kettering Cancer Center
Consulting or Advisory Role - Chugai Pharma; Santa Maria Biotherapeutics
Research Funding - Lilly (Inst)
 
Sophie Callies
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Ji Lin
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Volker Wacheck
Employment - Lilly
Stock and Other Ownership Interests - Lilly
Patents, Royalties, Other Intellectual Property - Lilly (Inst)
 
Shubham Pant
Consulting or Advisory Role - Celgene (Inst); Halozyme (Inst)
 
Todd Michael Bauer
Research Funding - Lilly (Inst)
 
Johanna C. Bendell
No Relationships to Disclose